April 27, 2022 -- Lonza and Integral Molecular are collaborating on a strategy to better assess the risks of off-target binding of biologic drug candidates because unwanted immunogenicity can have severe consequences for patients and jeopardize drug development programs.
Lonza's Early Development Services focuses on cell-based assays to evaluate the activity of biologic therapies upon binding. Integral Molecular de-risks therapeutic molecules by detecting off-target binding liabilities using its Membrane Proteome Array platform.
The collaboration will cover the full spectrum of in vitro immunosafety testing and allow customers to save time and resources by identifying and mitigating potential clinical risks earlier on, the firms said.
Copyright © 2022 scienceboard.net